Are BNP Changes During Hospitalization for Heart Failure a Reliable Surrogate for Predicting the Effects of Therapies on Post-Discharge Mortality?

Journal of the American College of Cardiology

Volumn 53, Issue 25, 2009, Pages 2349-2352

  Gheorghiade, Mihai ^a   Pang, Peter S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

acute decompensation of heart failure; B type natriuretic peptide; dobutamine; levosimendan; prognosis

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ETANERCEPT; LEVOSIMENDAN; MILRINONE; MOXONIDINE; NESIRITIDE; NITROGEN; PROSTACYCLIN; SODIUM; TEZOSENTAN; TOLVAPTAN; UREA;

ACUTE HEART FAILURE; AGE DISTRIBUTION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; DISEASE MARKER; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PATIENT DISCHARGE;

EID: 66949126764     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.01.075     Document Type: Editorial

References (36)

1. Maisel A., Mueller C., Adams Jr. K., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10 (2008) 824-839
2. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1412
3. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343 (1994) 440-444
4. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
5. Shah M.R., Hasselblad V., Tasissa G., et al. Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am J Cardiol 100 (2007) 1427-1433
6. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
7. Hobbs R., and Mills R.M. Endogenous B-type natriuretic peptide: a limb of the regulatory response to acutely decompensated heart failure. Clin Cardiol 31 (2008) 407-412
8. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 (2007) 2357-2368
9. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
10. Gheorghiade M., Zannad F., Sopko G., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
11. Cohen-Solal A., Logeart D., Huang B., Cai D., Nieminen M.S., and Mebazaa A. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 53 (2009) 2343-2348
12. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 (2001) 21-29
13. Fang J., Mensah G.A., Croft J.B., and Keenan N.L. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52 (2008) 428-434
14. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
15. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
16. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute wxacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
17. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
18. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297 (2007) 1319-1331
19. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298 (2007) 2009-2019
20. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297 (2007) 1883-1891
21. Packer M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy-2 (REVIVE-2) trial. Paper presented at: Late-breaking Clinical Trials, American Heart Association, Annual Scientific Session; November 13-16 (2005) Dallas, TX
22. Beohar N., Erdogan A.K., Lee D.C., et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol 52 (2008) 13-16
23. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 (2003) 997-1003
24. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327 (1992) 227-233
25. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
26. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294 (2005) 1625-1633
27. Cohn J.N., Pfeffer M.A., Rouleau J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003) 659-667
28. Klein L., Massie B.M., Leimberger J.D., et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinione for Exacerbation of Chronic Heart Failure (OPTIME-CHF). Circulation: Heart Failure 1 (2008) 25-33
29. Shah M.R., Stinnett S.S., McNulty S.E., et al. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. Am Heart J 141 (2001) 908-914
30. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
31. Blair J.E., Khan S., Konstam M.A., et al., EVEREST Investigators. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J (2009) May 2 [E-pub ahead of print]
32. Gheorghiade M., Abraham W.T., Albert N.M., et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 28 (2007) 980-988
33. Gheorghiade M., Zimmer C., Krasa H., et al. Effects of tolvaptan on long-term outcomes and short-term clinical status in the EVEREST trial: results of prespecified subgroup analyses. Paper presented at: Late-Breaking Clinical Trial European Society of Cardiology Heart Failure Congress; June 16 (2008) Milan, Italy
34. Swedberg K., Bristow M.R., Cohn J.N., et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105 (2002) 1797-1803
35. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
36. Wang N.C., Maggioni A.P., Konstam M.A., et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 299 (2008) 2656-2666